Astel­las pur­sues ‘con­vert­ible’ in vi­vo CAR-T cell ther­a­pies with Kelo­nia Ther­a­peu­tics

Astel­las is pen­ning a deal with Kelo­nia Ther­a­peu­tics to de­vel­op in vi­vo cell ther­a­pies to treat can­cer, but with a twist.

Not on­ly would the treat­ments be off-the-shelf, mean­ing that they would not have to be tai­lored to each pa­tient as cur­rent CAR-T ther­a­pies are, but the two com­pa­nies plan to en­gi­neer them to be “con­vert­ible” — the CAR-T cells could be turned on and off us­ing an an­ti­body.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.